On Wednesday, Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported second-quarter 2024 sales of $4.16 billion, beating the consensus of $4.06 billion. Revenues increased 7% year-over-year and 11% on constant currency, mainly due to higher revenues from generic products in all segments and…
Continue reading...